Posts by Team VIVA!
The future of medicine is not a ‘one-size-fits-all’ – July 8, 2016
Research and Markets, a world-renowned market research report hub, recently released their new Global DNA Sequencing Products Market 2016-2020 report that identified personalised medicine and global DNA sequencing products as the next big trend in medical rese arch. According to the report, DNA sequencing technology can be applied in diagnostics, drug and biomarker discovery, agriculture,…
Read MoreVIC pharmacies now permitted to administer flu shots – July 7, 2016
Victoria has fallen into line with the rest of Australia, permitting community pharmacies to administer flu shots. In May, 2016, the Victorian branches of the Pharmaceutical Society of Australia (PSA) and the Pharmacy Guild of Australia, publicly welcomed the Victorian Government’s approval for National Immunisation Program (NIP)-funded flu vaccines to be administered in pharmacy. A…
Read MoreTGA video warns of risks associated with buying medicine online – July 5, 2016
A new, no-nonsense, 90-second cartoon developed by Australian medication regulator, the Therapeutic Goods Administration (TGA), warns consumers to avoid risks associated with purchasing medications or medical devices online. The cartoon features animated “baddies” wearing masks and balaclavas, to demonstrate that not all medications available for purchase online, are legally manufactured, contain the correct dose of…
Read MoreWest Australian expert urges TGA to make codeine a prescription only treatment – July 5, 2016
As the Therapeutic Goods Administration (TGA) considers the scheduling of pain-killing medication, codeine, Professor Stephan Schug, Director of Pain Medicine at Royal Perth Hospital and Chair of Anaesthesiology, University of Western Australia, has urged the regulator to make the medication prescription-only. Prof Schug argues codeine is a poor pain management therapy when used on its…
Read MoreLife-saving drug now available to Australian infants living with HT-1 – June 30, 2016
Australian infants and children living with a rare, inherited genetic disease known as Hereditary Tyrosinaemia Type 1 (HT-1) are now eligible to receive the life-saving treatment, Orfadin (insert chemical compound) under the Life Savings Drug Program (LSDP). In newborns living with the rare, genetic metabolic disorder, the baby lacks the ability to break down the…
Read More